{"id":"dasiglucagon","rwe":[],"_fda":{"id":"48d68219-2ba1-426f-a5a0-0cc35e69ff19","set_id":"14704879-872c-4967-8779-04a3bbdfb4e6","openfda":{"nui":["N0000190852","N0000193923","N0000009345"],"unii":["AD4J2O47FQ"],"route":["SUBCUTANEOUS"],"rxcui":["2535238","2535243","2535247","2535249"],"spl_id":["48d68219-2ba1-426f-a5a0-0cc35e69ff19"],"brand_name":["Zegalogue"],"spl_set_id":["14704879-872c-4967-8779-04a3bbdfb4e6"],"package_ndc":["0169-1913-01","0169-1913-12","0169-1913-02","0169-1912-01","0169-1912-12","0169-1912-02"],"product_ndc":["0169-1912","0169-1913"],"generic_name":["DASIGLUCAGON"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Increased Glycogenolysis [PE]"],"substance_name":["DASIGLUCAGON"],"pharm_class_epc":["Antihypoglycemic Agent [EPC]"],"pharm_class_moa":["Glucagon Receptor Agonists [MoA]"],"manufacturer_name":["Novo Nordisk"],"application_number":["NDA214231"],"is_original_packager":[true]},"version":"2","pregnancy":["8.1 Pregnancy Risk Summary There are no available data on dasiglucagon use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated hypoglycemia in pregnancy can cause complications and may be fatal. In animal reproduction studies, daily subcutaneous administration of dasiglucagon to pregnant rabbits and rats during the period of organogenesis did not cause adverse developmental effects at exposures 7 and 709 times the human dose of 0.6 mg based on AUC, respectively (see Data ) . Data Animal Data In an embryo-fetal development study, pregnant rats were treated daily with subcutaneous doses of 2, 10, and 24 mg/kg/day during the period of organogenesis (gestation day 6 to 17). Maternal toxicity, in terms of decreased body weight gain, lower fetal body weight, and delayed bone ossification, was observed at ≥10 mg/kg/day (≥475 times the human dose, based on AUC). In an embryo-fetal development study, pregnant rabbits were treated daily with subcutaneous doses of 0.1, 0.3, and 1 mg/kg/day during the period of organogenesis (gestation day 6 to 19). Lower fetal body weight and delayed bone ossification were observed at 1 mg/kg/day (100 times the human dose, based on AUC), a dose that also induced maternal toxicity in terms of decreased body weight gain. At ≥0.3 mg/kg/day (≥20 times the human dose), dasiglucagon caused fetal skeletal and visceral malformations. No adverse fetal developmental effects were observed at 0.1 mg/kg/day, corresponding to exposure 7 times the human dose."],"overdosage":["10 OVERDOSAGE If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, and/or increases in blood pressure and heart rate. In case of suspected overdosing, serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a marked increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed. Appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms."],"description":["11 DESCRIPTION ZEGALOGUE contains dasiglucagon hydrochloride, which is a glucagon analog and an antihypoglycemic agent. Dasiglucagon is comprised of 29 amino acids. The molecular formula of dasiglucagon (anhydrous, free-base) is C 152 H 222 N 38 O 50 , and its molecular mass is 3382 g/mol (anhydrous, free-base). Dasiglucagon hydrochloride has the following chemical structure: ZEGALOGUE injection is a preservative free, sterile, aqueous, clear, and colorless solution for subcutaneous use in a single-dose prefilled syringe and an autoinjector. Each prefilled syringe and autoinjector contains 0.63 mg of dasiglucagon provided as dasiglucagon hydrochloride, which is a salt with 3 - 5 equivalents of hydrochloride, and contains the following inactive ingredients: 3.82 mg tromethamine, 6.44 mg sodium chloride, and water for injection. Hydrochloric acid and/or sodium hydroxide may have been added to adjust pH to 6.5. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied ZEGALOGUE injection is a clear, colorless solution supplied as follows: Presentation Strength Package Size NDC Single-dose autoinjector 0.6 mg/0.6 mL 1 0169-1912-01 Single-dose autoinjector 0.6 mg/0.6 mL 2 0169-1912-02 Single-dose prefilled syringe 0.6 mg/0.6 mL 1 0169-1913-01 Single-dose prefilled syringe 0.6 mg/0.6 mL 2 0169-1913-02 16.2 Recommended Storage Store ZEGALOGUE in a refrigerator, 2°C to 8°C (36°F to 46°F). Keep away from the cooling element. Do not freeze. ZEGALOGUE can be kept at room temperature between 20°C to 25°C (68°F to 77°F) for up to 12 months. Record the date when the product was removed from the refrigerator in the space provided on the protective case. Do not return the product to the refrigerator after storing at room temperature. Store in the provided protective case and protect from light. Discard ZEGALOGUE after the end of the 12-month period at room temperature storage, or after the expiration date stated on the product, whichever occurs first. The inside of the gray cap on ZEGALOGUE autoinjector contains dry natural rubber (a derivative of latex). The inside of the gray needle cover on ZEGALOGUE prefilled syringe contains dry natural rubber (a derivative of latex)."],"geriatric_use":["8.5 Geriatric Use Clinical studies of ZEGALOGUE included too few patients 65 years of age and older to determine whether these patients respond differently from younger adult patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of ZEGALOGUE for the treatment of severe hypoglycemia in patients with diabetes have been established in pediatric patients aged 6 years and above. Use of ZEGALOGUE for this indication is supported by evidence from a study in 42 pediatric patients with type 1 diabetes [see Clinical Studies (14.2) ] . The safety and effectiveness of ZEGALOGUE have not been established in pediatric patients younger than 6 years of age."],"effective_time":"20230101","clinical_studies":["14 CLINICAL STUDIES Three randomized, double-blind, placebo-controlled, multicenter trials were conducted in patients with type 1 diabetes. Two trials (Trial A and Trial B) were conducted in adult patients, and one trial (Trial C) was conducted in pediatric patients aged 6 to 17 years. In all 3 trials, patients were randomized to ZEGALOGUE 0.6 mg, placebo, or (in Trials A and C) glucagon for injection 1.0 mg. ZEGALOGUE and the comparators were administered as single subcutaneous injections following a controlled induction of hypoglycemia using intravenous administration of insulin. During this procedure, a plasma glucose concentration of <60 mg/dL was targeted in Trials A and B, whereas the target was <80 mg/dL in Trial C. The primary efficacy endpoint for all 3 trials was time to plasma glucose recovery (treatment success), defined as an increase in blood glucose of ≥20 mg/dL from time of administration, without additional intervention within 45 minutes. In Trials A and B, plasma glucose values were collected and assessed at pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 45, 50, 60, 75, 90 minutes after treatment. Trial C assessed plasma glucose at the same timepoints as did Trials A and B, with the exception of the 25, 40, 50, 75 and 90-minute post-treatment timepoints. The primary hypothesis test was superiority of ZEGALOGUE versus placebo. There was no formal hypothesis test of ZEGALOGUE versus glucagon for injection. 14.1 Adult Patients Trial A, NCT03378635: A total of 170 patients were randomized 2:1:1 to ZEGALOGUE, placebo, and glucagon for injection, stratified by injection sites (abdominal region, buttocks, thigh). The mean age of the patients was 39.1 years (96% were < 65 years), and the mean duration of diabetes was 20.0 years; 63% were male; 92% were White. The mean baseline plasma glucose was 58.8 mg/dL. The median time to plasma glucose recovery was statistically significantly shorter for ZEGALOGUE (10 minutes) versus placebo (40 minutes) (Table 4). Figure 3 shows the cumulative proportions of patients achieving plasma glucose recovery over time. The median time to plasma glucose recovery was numerically similar between ZEGALOGUE (10 minutes) and glucagon for injection (12 minutes). Trial B, NCT03688711: A total of 45 patients were randomized 3:1 to ZEGALOGUE and placebo stratified by injection sites (buttocks, deltoid). The mean age of the patients was 41.0 years (95% were < 65 years), and the mean duration of diabetes was 22.5 years; 57% were male; 93% were White. The mean baseline plasma glucose was 55.0 mg/dL. The median time to plasma glucose recovery was statistically significantly shorter for ZEGALOGUE (10 minutes) versus placebo (35 minutes) (Table 4). Table 4. Plasma Glucose Recovery in Adult Patients Trial A Trial B ZEGALOGUE N=82 Placebo N=43 ZEGALOGUE N=34 Placebo N=10 N is the number of patients who were randomized and treated. Median time to recovery [95% CI log-log confidence interval ] 10 min [10; 10] p < 0.001 versus placebo (log-rank test stratified by injection sites) 40 min [30; 40] 10 min [8; 12] 35 min [20; -) Figure 3 Time to plasma glucose recovery in Trial A Figure 3 14.2 Pediatric Patients Trial C, NCT03667053: Pediatric patients aged 6 to 17 years and weighing ≥20 kg, were randomized 2:1:1 to ZEGALOGUE, placebo, and glucagon for injection, stratified by injection sites (abdominal region, thigh) and age groups (6-11 years and 12-17 years). A total of 42 patients were randomized. The mean age was 12.5 years (range 7 to 17 years), and the mean duration of diabetes was 5.9 years; 56% were male; 95% were White. The mean baseline plasma glucose was 72.0 mg/dL. The median time to plasma glucose recovery was statistically significantly shorter for ZEGALOGUE (10 minutes) versus placebo (30 minutes) (Table 5). Figure 4 shows the cumulative proportions of pediatric patients achieving plasma glucose recovery over time. The median time to plasma glucose recovery was numerically similar between ZEGALOGUE (10 minutes) and glucagon for injection (10 minutes). Table 5. Plasma Glucose Recovery in Pediatric Patients Trial C ZEGALOGUE N=20 Placebo N=11 N is the number of patients who were randomized and treated. Median time to recovery [95% CI log-log confidence interval ] 10 min [8; 12] p < 0.001 versus placebo (log-rank test stratified by injection site and age group) 30 min [20; -) Figure 4. Time to plasma glucose recovery in Trial C Figure 4"],"pharmacodynamics":["12.2 Pharmacodynamics After administration of ZEGALOGUE in adult patients with type 1 diabetes, the mean glucose increase from baseline at 90 minutes was 168 mg/dL (Figure 1). Figure 1. Mean plasma glucose over time in adults with type 1 diabetes administered 0.6 mg dasiglucagon In pediatric patients (7 to 17 years) with type 1 diabetes, the mean glucose increase at 60 minutes after administration of ZEGALOGUE was 162 mg/dL (Figure 2). Figure 2. Mean plasma glucose over time in pediatric patients with type 1 diabetes administered 0.6 mg dasiglucagon Cardiac Electrophysiology At a dose resulting in more than 5 times the concentration achieved with the recommended therapeutic dose, ZEGALOGUE does not prolong the QT interval to any clinically relevant extent. Figure 1 Figure 2"],"pharmacokinetics":["12.3 Pharmacokinetics Absorption ZEGALOGUE absorption following subcutaneous injection of 0.6 mg resulted in a mean peak plasma concentration of 5110 pg/mL (1510 pmol/L) at around 35 minutes. Distribution The mean apparent volume of distribution was 47 L to 57 L following subcutaneous administration. Elimination The half-life was approximately 30 minutes. Metabolism Metabolism data indicated that dasiglucagon is cleared like native glucagon through proteolytic degradation pathways in blood, liver, and kidney. Specific Populations After administration of ZEGALOGUE in pediatric patients with type 1 diabetes, the mean peak plasma concentration of 3920 pg/mL occurred at around 21 minutes."],"adverse_reactions":["6 ADVERSE REACTIONS The following important adverse reactions are described elsewhere in the labeling: • Hypersensitivity and Allergic Reactions [see Warnings and Precautions (5.3) ] Most common adverse reactions (≥2%) associated with ZEGALOGUE are: Adults: nausea, vomiting, headache, diarrhea, and injection site pain Pediatrics: nausea, vomiting, headache, and injection site pain ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc., at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of ZEGALOGUE cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, 316 adult patients with type 1 diabetes and 20 pediatric patients with type 1 diabetes were exposed to ZEGALOGUE. The data in Table 1 reflect exposure of 116 adult patients to ZEGALOGUE in 2 placebo-controlled trials (mean age 40 years). Table 2 reflects exposure of 20 pediatric patients exposed to ZEGALOGUE in a placebo-controlled trial. Eight patients were 7 to 11 years old, and 12 were 12 to 17 years old [see Clinical Studies (14) ] . Table 1. Adverse Reactions Occurring ≥2% and More Frequently than with Placebo in ZEGALOGUE-treated Adult Patients within 12 hours of Treatment in 2 Placebo-Controlled Trials Adverse reaction type Placebo (N=53) Dasiglucagon (N=116) % of Patients % of Patients Nausea 4% 57% Vomiting 2% 25% Headache 4% 11% Diarrhea 0% 5% Injection site pain 0% 2% Table 2. Adverse Reactions Occurring ≥2% and More Frequently than with Placebo in ZEGALOGUE-treated Pediatric Patients within 12 hours of Treatment in a Placebo-Controlled Trial Adverse reaction type Placebo (N=11) Dasiglucagon Age 6-11 years (N=8) Dasiglucagon Age 12-17 years (N=12) Dasiglucagon All (N=20) % of Patients % of Patients % of Patients % of Patients Nausea 0% 25% 92% 65% Vomiting 0% 25% 67% 50% Headache 0% 0% 17% 10% Injection site pain 0% 0% 8% 5% Other Adverse Reactions Other adverse reactions in patients treated with dasiglucagon occurring within 12 hours of treatment include: hypertension, hypotension, bradycardia, presyncope, palpitations, and orthostatic intolerance. 6.2 Immunogenicity As with all therapeutic peptides, there is a potential for immunogenicity with ZEGALOGUE. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ZEGALOGUE with the incidence of antibodies to other products may be misleading. In clinical trials, 4/498 (<1%) of ZEGALOGUE-treated patients developed treatment-emergent anti-drug antibodies (ADAs). Two patients receiving a single dose of ZEGALOGUE had detectable ADAs to dasiglucagon for at least 14 months after dosing. One ADA-positive patient receiving multiple doses of ZEGALOGUE had ADAs with transient neutralizing activity and with cross-reactivity against native glucagon. Although no safety or efficacy concerns were noted for these ADA-positive subjects, it is unknown whether ADAs may affect pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of the drug [see Clinical Studies (14) ] ."],"contraindications":["4 CONTRAINDICATIONS ZEGALOGUE is contraindicated in patients with: • Pheochromocytoma because of the risk of substantial increase in blood pressure [see Warnings and Precautions (5.1) ] • Insulinoma because of the risk of hypoglycemia [see Warnings and Precautions (5.2) ] Pheochromocytoma ( 4 ) Insulinoma ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Table 3. Clinically Significant Drug Interactions with ZEGALOGUE Beta-Blockers Clinical Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE. Indomethacin Clinical Impact: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may even produce hypoglycemia. Warfarin Clinical Impact: ZEGALOGUE may increase the anticoagulant effect of warfarin. • Beta-blockers: Patients taking beta-blockers may have a transient increase in pulse and blood pressure. ( 7 ) • Indomethacin: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may produce hypoglycemia. ( 7 ) • Warfarin: ZEGALOGUE may increase the anticoagulant effect of warfarin. ( 7 )"],"how_supplied_table":["
PresentationStrengthPackage SizeNDC
Single-dose autoinjector0.6 mg/0.6 mL10169-1912-01
Single-dose autoinjector0.6 mg/0.6 mL20169-1912-02
Single-dose prefilled syringe0.6 mg/0.6 mL10169-1913-01
Single-dose prefilled syringe0.6 mg/0.6 mL20169-1913-02
"],"mechanism_of_action":["12.1 Mechanism of Action Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect."],"instructions_for_use":["INSTRUCTIONS FOR USE ZEGALOGUE ® (ze' gah log) (dasiglucagon) injection 0.6 mg/0.6 mL Emergency Use for Very Low Blood Sugar Single-Dose Prefilled Syringe Injection, for subcutaneous use Important: ZEGALOGUE is used to treat very low blood sugar (severe hypoglycemia) where you need help from others. ZEGALOGUE contains 1 dose of dasiglucagon in a prefilled syringe and cannot be reused. Read and understand this Instructions For Use before an emergency happens. Show your family and friends where you keep ZEGALOGUE and explain how to use it by sharing these instructions, so they know how to use ZEGALOGUE before an emergency happens. The inside of the gray needle cover contains dry natural rubber, which may cause allergic reactions in people with latex allergy. Read before Injecting ZEGALOGUE • Do not use ZEGALOGUE if the: o expiration date has passed o gray needle cover is missing or o syringe appears damaged • When opening the red protective case make sure to hold it up straight (with the gray cap on top) to avoid dropping ZEGALOGUE. • Do not remove the gray needle cover until you are ready to inject ZEGALOGUE. • For questions or more information about ZEGALOGUE, call your healthcare provider. Storage information • Store ZEGALOGUE in the refrigerator between 36°F to 46°F (2°C to 8°C). • Do not freeze. • Store ZEGALOGUE in the red protective case it comes in. • ZEGALOGUE can also be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 12 months. See example to the right for how to keep track of this 12-month period. • Do not return to refrigerator after storing at room temperature. • Throw away ZEGALOGUE if it has been stored at room temperature for more than 12 months. • Replace ZEGALOGUE before the expiration date printed on the red protective case. • Keep ZEGALOGUE and all medicines out of the reach of children. Description of parts Before injection Choose injection site and expose skin Injection sites include: • Outer upper arms • Lower abdomen (at least 2 inches from the belly button) • Front or back of thighs • Buttocks Roll back any clothing to expose bare skin. Do not inject through clothes. Hold the red protective case upright and remove gray cap • Hold the red protective case upright with the gray cap on top. • Pull the gray cap up to open. • Carefully remove ZEGALOGUE from the red protective case without dropping it. How to inject Step 1 Remove the gray needle cover Pull the gray needle cover straight off. Be careful not to bend the needle. Step 2 Pinch the skin and insert the needle Gently pinch the skin and insert the entire needle into the skin at a 45° angle. Step 3 Give the injection After inserting the needle, release the pinched skin and slowly press the plunger rod all the way down until the syringe is empty and the plunger rod stops. Step 4 Remove the needle After the plunger rod stops and the injection is complete, carefully remove the needle from the injection site. After injection • After you have given the injection, roll the unconscious person on to their side to prevent choking. • Call for emergency medical help or a healthcare provider right away after you have injected ZEGALOGUE. Even if the ZEGALOGUE injection helps the person to wake up, still call for emergency medical help right away. If the person does not respond after 15 minutes, another dose may be given, if available. • Once the person is able to safely consume food or drink, give the person a fast-acting source of sugar (such as fruit juice) and a long-acting source of sugar (such as crackers with cheese or peanut butter). • Replace the used ZEGALOGUE right away so you will have a new ZEGALOGUE in case you need it. Hypoglycemia may happen again after receiving ZEGALOGUE treatment. Early symptoms of hypoglycemia may include: • sweating • drowsiness • dizziness • sleep disturbances • irregular heartbeat (palpitation) • anxiety • tremor • blurred vision • hunger • slurred speech • restlessness • depressed mood • tingling in the hands, feet, lips, or tongue • irritability • abnormal behavior • lightheadedness • unsteady movement • inability to concentrate • personality changes • headache If not treated early, hypoglycemia may worsen and the person may have severe hypoglycemia. Signs of severe hypoglycemia include confusion, seizures, unconsciousness, and death. How to throw away (dispose of) ZEGALOGUE Dispose of your ZEGALOGUE and the gray needle cover in an FDA-cleared sharps disposal container. Put your expired or used needles and syringes in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: • made of a heavy-duty plastic • can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out • upright and stable during use • leak-resistant • properly labeled to warn of hazardous waste inside the container When your sharps disposal container is almost full, you will need to follow your community guidelines for the correct way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit it. Do not recycle your used sharps disposal container. This Instructions For Use has been approved by the U.S. Food and Drug Administration. Distributed by: Novo Nordisk Inc., Plainsboro, NJ, USA Manufactured by: Rechon Life Science AB, Malmö, Sweden Revised 01/2023 Figure PFS-description.jpg Figure Figure Figure Figure Figure Figure Figure","INSTRUCTIONS FOR USE ZEGALOGUE ® (ze' gah log) (dasiglucagon) injection 0.6 mg/0.6 mL Emergency Use for Very Low Blood Sugar Single-Dose Autoinjector Injection, for subcutaneous use Important: ZEGALOGUE is used to treat very low blood sugar (severe hypoglycemia) where you need help from others. ZEGALOGUE contains 1 dose of dasiglucagon in a prefilled autoinjector and cannot be reused. Read and understand this Instructions For Use before an emergency happens. Show your family and friends where you keep ZEGALOGUE and explain how to use it by sharing these instructions, so they know how to use ZEGALOGUE before an emergency happens. The inside of the gray cap contains dry natural rubber, which may cause allergic reactions in people with latex allergy. Read before injecting ZEGALOGUE • Do not use ZEGALOGUE if the: o expiration date has passed o gray cap is missing or o autoinjector appears damaged • When opening the red protective case make sure to hold it up straight (with the gray lid on top) to avoid dropping ZEGALOGUE. • Do not remove the gray cap until you are ready to inject ZEGALOGUE. • For questions or more information about ZEGALOGUE, call your healthcare provider. Storage information • Store ZEGALOGUE in the refrigerator between 36°F to 46°F (2°C to 8°C). • Do not freeze. • Store ZEGALOGUE in the red protective case it comes in. • ZEGALOGUE can also be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 12 months. See example to the right for how to keep track of this 12-month period. • Do not return to refrigerator after storing at room temperature. • Throw away ZEGALOGUE if it has been stored at room temperature for more than 12 months. • Replace ZEGALOGUE before the expiration date printed on the red protective case. • Keep ZEGALOGUE and all medicines out of the reach of children. Description of parts Before injection Choose injection site and expose skin Injection sites include: • Outer upper arms • Lower abdomen (at least 2 inches from the belly button) • Front or back of thighs • Buttocks Roll back any clothing to expose bare skin. Do not inject through clothes. Hold the red protective case upright and remove gray lid • Hold the red protective case upright with the gray lid on top. • Pull the gray lid up to open. • Carefully remove ZEGALOGUE from the red protective case without dropping it. How to inject Step 1 Remove the gray cap from needle end Pull the gray cap straight off. Do not put your hand or fingers anywhere near the yellow needle guard. Touching the yellow needle guard may cause an accidental needle stick injury. Step 2 Push and hold down ZEGALOGUE for 10 seconds and check window is red Push ZEGALOGUE straight down on skin until the yellow needle guard is fully pressed down. You may hear the first click. Keep holding ZEGALOGUE down and slowly count to 10 seconds. During this time the medicine window will turn red and you may hear a second click. Check that the medicine window is red, which means that the full dose has been given. Step 3 Remove ZEGALOGUE from injection site Remove ZEGALOGUE by lifting it straight up. The yellow needle guard will cover the needle and lock, preventing an accidental needle stick injury. After injection • After you have given the injection, roll the unconscious person on to their side to prevent choking. • Call for emergency medical help or a healthcare provider right away after you have injected ZEGALOGUE. Even if the ZEGALOGUE injection helps the person to wake up, still call for emergency medical help right away. If the person does not respond after 15 minutes, another dose may be given, if available. • Once the person is able to safely consume food or drink, give the person a fast-acting source of sugar (such as fruit juice) and a long-acting source of sugar (such as crackers with cheese or peanut butter). • Replace the used ZEGALOGUE right away so you will have a new ZEGALOGUE in case you need it. Hypoglycemia may happen again after receiving ZEGALOGUE treatment. Early symptoms of hypoglycemia may include: • sweating • drowsiness • dizziness • sleep disturbances • irregular heartbeat (palpitation) • anxiety • tremor • blurred vision • hunger • slurred speech • restlessness • depressed mood • tingling in the hands, feet, lips, or tongue • irritability • abnormal behavior • lightheadedness • unsteady movement • inability to concentrate • personality changes • headache If not treated early, hypoglycemia may worsen and the person may have severe hypoglycemia. Signs of severe hypoglycemia include confusion, seizures, unconsciousness, and death. How to throw away (dispose of) ZEGALOGUE Dispose of your ZEGALOGUE and gray cap in an FDA-cleared sharps disposal container. Put your expired or used ZEGALOGUE in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) autoinjectors, loose needles and syringes in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: • made of a heavy-duty plastic • can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out • upright and stable during use • leak-resistant • properly labeled to warn of hazardous waste inside the container When your sharps disposal container is almost full, you will need to follow your community guidelines for the correct way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used autoinjectors. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit it. Do not recycle your used sharps disposal container. This Instructions For Use has been approved by the U.S. Food and Drug Administration. Distributed by: Novo Nordisk Inc., Plainsboro, NJ, USA Manufactured by: Rechon Life Science AB, Malmö, Sweden Revised 01/2023 Figure AI-description.jpg Figure Figure Figure Figure Figure Figure Figure"],"storage_and_handling":["16.2 Recommended Storage Store ZEGALOGUE in a refrigerator, 2°C to 8°C (36°F to 46°F). Keep away from the cooling element. Do not freeze. ZEGALOGUE can be kept at room temperature between 20°C to 25°C (68°F to 77°F) for up to 12 months. Record the date when the product was removed from the refrigerator in the space provided on the protective case. Do not return the product to the refrigerator after storing at room temperature. Store in the provided protective case and protect from light. Discard ZEGALOGUE after the end of the 12-month period at room temperature storage, or after the expiration date stated on the product, whichever occurs first. The inside of the gray cap on ZEGALOGUE autoinjector contains dry natural rubber (a derivative of latex). The inside of the gray needle cover on ZEGALOGUE prefilled syringe contains dry natural rubber (a derivative of latex)."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect. 12.2 Pharmacodynamics After administration of ZEGALOGUE in adult patients with type 1 diabetes, the mean glucose increase from baseline at 90 minutes was 168 mg/dL (Figure 1). Figure 1. Mean plasma glucose over time in adults with type 1 diabetes administered 0.6 mg dasiglucagon In pediatric patients (7 to 17 years) with type 1 diabetes, the mean glucose increase at 60 minutes after administration of ZEGALOGUE was 162 mg/dL (Figure 2). Figure 2. Mean plasma glucose over time in pediatric patients with type 1 diabetes administered 0.6 mg dasiglucagon Cardiac Electrophysiology At a dose resulting in more than 5 times the concentration achieved with the recommended therapeutic dose, ZEGALOGUE does not prolong the QT interval to any clinically relevant extent. Figure 1 Figure 2 12.3 Pharmacokinetics Absorption ZEGALOGUE absorption following subcutaneous injection of 0.6 mg resulted in a mean peak plasma concentration of 5110 pg/mL (1510 pmol/L) at around 35 minutes. Distribution The mean apparent volume of distribution was 47 L to 57 L following subcutaneous administration. Elimination The half-life was approximately 30 minutes. Metabolism Metabolism data indicated that dasiglucagon is cleared like native glucagon through proteolytic degradation pathways in blood, liver, and kidney. Specific Populations After administration of ZEGALOGUE in pediatric patients with type 1 diabetes, the mean peak plasma concentration of 3920 pg/mL occurred at around 21 minutes."],"indications_and_usage":["1 INDICATIONS AND USAGE ZEGALOGUE ® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. ZEGALOGUE is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Substantial Increase in Blood Pressure in Patients with Pheochromocytoma: Contraindicated in patients with pheochromocytoma because ZEGALOGUE may stimulate the release of catecholamines from the tumor. ( 4 , 5.1 ) • Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose, but ZEGALOGUE may stimulate exaggerated insulin release from an insulinoma and cause subsequent hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE, give glucose orally or intravenously. ( 4 , 5.2 ) • Hypersensitivity and Allergic Reactions: Allergic reactions have been reported with glucagon products and may include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. ( 5.3 ) • Lack of Efficacy in Patients with Decreased Hepatic Glycogen: ZEGALOGUE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for ZEGALOGUE to be effective. Patients with these conditions should be treated with glucose. ( 5.4 ) 5.1 Substantial Increase in Blood Pressure in Patients with Pheochromocytoma ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor [see Contraindications (4) ] . If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. 5.2 Hypoglycemia in Patients with Insulinoma In patients with insulinoma, administration of glucagon products may produce an initial increase in blood glucose; however, ZEGALOGUE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. ZEGALOGUE is contraindicated in patients with insulinoma [see Contraindications (4) ] . If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE, give glucose orally or intravenously. 5.3 Hypersensitivity and Allergic Reactions Allergic reactions have been reported with glucagon products; these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions. 5.4 Lack of Efficacy in Patients with Decreased Hepatic Glycogen ZEGALOGUE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for ZEGALOGUE administration to be effective. Patients with these conditions should be treated with glucose."],"clinical_studies_table":["
Table 4. Plasma Glucose Recovery in Adult Patients
Trial ATrial B
ZEGALOGUE N=82Placebo N=43ZEGALOGUE N=34Placebo N=10
N is the number of patients who were randomized and treated.
Median time to recovery [95% CIlog-log confidence interval]10 min [10; 10]p < 0.001 versus placebo (log-rank test stratified by injection sites)40 min [30; 40]10 min [8; 12]35 min [20; -)
","
Table 5. Plasma Glucose Recovery in Pediatric Patients
Trial C
ZEGALOGUE N=20Placebo N=11
N is the number of patients who were randomized and treated.
Median time to recovery [95% CIlog-log confidence interval]10 min [8; 12]p < 0.001 versus placebo (log-rank test stratified by injection site and age group)30 min [20; -)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long-term studies in animals to evaluate carcinogenicity of dasiglucagon have not been performed. Mutagenesis Dasiglucagon was not mutagenic or clastogenic in a standard battery of genotoxicity tests: bacterial mutagenicity (Ames), human lymphocyte chromosome aberration, and rat bone marrow micronucleus. Impairment of Fertility In a fertility and early embryofetal development study in rats, dasiglucagon administered by subcutaneous injection (0.5, 2, and 8 mg/kg/day) did not impair fertility in male and female rats at exposures 179 and 269 times the human dose of 0.6 mg (based on AUC), respectively."],"adverse_reactions_table":["
Table 1. Adverse Reactions Occurring ≥2% and More Frequently than with Placebo in ZEGALOGUE-treated Adult Patients within 12 hours of Treatment in 2 Placebo-Controlled Trials
Adverse reaction typePlacebo (N=53) Dasiglucagon (N=116)
% of Patients% of Patients
Nausea4%57%
Vomiting2%25%
Headache4%11%
Diarrhea0%5%
Injection site pain0%2%
","
Table 2. Adverse Reactions Occurring ≥2% and More Frequently than with Placebo in ZEGALOGUE-treated Pediatric Patients within 12 hours of Treatment in a Placebo-Controlled Trial
Adverse reaction typePlacebo (N=11)Dasiglucagon Age 6-11 years (N=8)Dasiglucagon Age 12-17 years (N=12)Dasiglucagon All (N=20)
% of Patients% of Patients% of Patients% of Patients
Nausea0%25%92%65%
Vomiting0%25%67%50%
Headache0%0%17%10%
Injection site pain0%0%8%5%
"],"drug_interactions_table":["ZEGALOGUE may increase the anticoagulant effect of warfarin.
Table 3. Clinically Significant Drug Interactions with ZEGALOGUE
Beta-Blockers
Clinical Impact:Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE.
Indomethacin
Clinical Impact:In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may even produce hypoglycemia.
Warfarin
Clinical Impact:
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient and family members or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions For Use). Recognition of Severe Hypoglycemia Inform patient and family members or caregivers on how to recognize the signs and symptoms of severe hypoglycemia and the risks of prolonged hypoglycemia. Administration Review the Patient Information and Instructions For Use with the patient and family members or caregivers. Serious Hypersensitivity Inform patients that allergic reactions can occur with glucagon products like ZEGALOGUE. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions [see Warnings and Precautions (5.3) ]."],"spl_unclassified_section":["Distributed by: Novo Nordisk Inc. Plainsboro, NJ, USA Manufactured by: Rechon Life Science AB Malmö, Sweden"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • ZEGALOGUE autoinjector and prefilled syringe are for subcutaneous injection only. ( 2.1 ) • The dose in adults and pediatric patients aged 6 years and older is 0.6 mg. ( 2.2 ) • Administer ZEGALOGUE according to the printed instructions on the protective case label and the Instructions For Use. ( 2.1 ) • Visually inspect ZEGALOGUE prior to administration. The solution should appear clear, colorless, and free from particles. If the solution is discolored or contains particulate matter, do not use. ( 2.1 ) • Administer the injection into the lower abdomen, buttocks, thigh, or outer upper arm. ( 2.1 ) • Call for emergency assistance immediately after administering the dose. ( 2.1 ) • If there has been no response after 15 minutes, an additional dose of ZEGALOGUE from a new device may be administered while waiting for emergency assistance. ( 2.1 ) • When the patient has responded to treatment, give oral carbohydrates. ( 2.1 ) • Do not attempt to reuse ZEGALOGUE. Each device contains a single dose of dasiglucagon and cannot be reused. ( 2.1 ) 2.1 Administration Instructions ZEGALOGUE autoinjector and prefilled syringe are for subcutaneous injection only. Instruct patients and their caregivers on the signs and symptoms of severe hypoglycemia. Because severe hypoglycemia requires the help of others to recover, instruct the patient to inform those around them about ZEGALOGUE and its Instructions For Use. Administer ZEGALOGUE as soon as possible when severe hypoglycemia is recognized. Instruct the patient or caregiver to read the Instructions For Use at the time they receive a prescription for ZEGALOGUE. Emphasize the following instructions to the patient or caregiver: • Administer ZEGALOGUE according to the printed instructions on the protective case label and the Instructions For Use. • Visually inspect ZEGALOGUE prior to administration. The solution should appear clear, colorless, and free from particles. If the solution is discolored or contains particulate matter, do not use. • Administer the injection in the lower abdomen, buttocks, thigh, or outer upper arm. • Call for emergency assistance immediately after administering the dose. • If there has been no response after 15 minutes, an additional dose of ZEGALOGUE may be administered while waiting for emergency assistance. • When the patient has responded to treatment, give oral carbohydrates to restore liver glycogen and prevent recurrence of hypoglycemia. • Do not attempt to reuse ZEGALOGUE. Each ZEGALOGUE device contains a single dose of dasiglucagon and cannot be reused. 2.2 Recommended Dosage The recommended dose of ZEGALOGUE in adults and pediatric patients aged 6 years and older is 0.6 mg administered by subcutaneous injection into the lower abdomen, buttocks, thigh, or outer upper arm. If there has been no response after 15 minutes, an additional 0.6 mg dose of ZEGALOGUE from a new device may be administered."],"spl_product_data_elements":["Zegalogue dasiglucagon TROMETHAMINE SODIUM CHLORIDE WATER HYDROCHLORIC ACID SODIUM HYDROXIDE DASIGLUCAGON DASIGLUCAGON Zegalogue dasiglucagon TROMETHAMINE SODIUM CHLORIDE WATER HYDROCHLORIC ACID SODIUM HYDROXIDE DASIGLUCAGON DASIGLUCAGON"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS ZEGALOGUE injection is a clear, colorless solution available as: • 0.6 mg/0.6 mL single-dose autoinjector • 0.6 mg/0.6 mL single-dose prefilled syringe Injection: • 0.6 mg/0.6 mL single-dose autoinjector ( 3 ) • 0.6 mg/0.6 mL single-dose prefilled syringe ( 3 )"],"instructions_for_use_table":["Do not use ZEGALOGUE if the:expiration date has passedgray needle cover is missing orsyringe appears damagedWhen opening the red protective case make sure to hold it up straight (with the gray cap on top) to avoid dropping ZEGALOGUE.Do not remove the gray needle cover until you are ready to inject ZEGALOGUE.For questions or more information about ZEGALOGUE, call your healthcare provider.
Read before Injecting ZEGALOGUE
•ooo•••
","Store ZEGALOGUE in the refrigerator between 36°F to 46°F (2°C to 8°C).Do not freeze.Store ZEGALOGUE in the red protective case it comes in.ZEGALOGUE can also be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 12 months. See example to the right for how to keep track of this 12-month period.Do not return to refrigerator after storing at room temperature.Throw away ZEGALOGUE if it has been stored at room temperature for more than 12 months.Replace ZEGALOGUE before the expiration date printed on the red protective case.Keep ZEGALOGUE and all medicines out of the reach of children.
Storage information
••••••••
","
Description of parts
","Outer upper armsLower abdomen (at least 2 inches from the belly button)Front or back of thighsButtocksRoll back any clothing to expose bare skin. Do not inject through clothes.Hold the red protective case upright with the gray cap on top.Pull the gray cap up to open.Carefully remove ZEGALOGUE from the red protective case without dropping it.
Before injection
Choose injection site and expose skinInjection sites include:
••••
Hold the red protective case upright and remove gray cap
•••
","
How to inject
Step 1Remove the gray needle coverPull the gray needle cover straight off. Be careful not to bend the needle.
Step 2Pinch the skin and insert the needleGently pinch the skin and insert the entire needle into the skin at a 45° angle.
Step 3Give the injectionAfter inserting the needle, release the pinched skin and slowly press the plunger rod all the way down until the syringe is empty and the plunger rod stops.
Step 4Remove the needleAfter the plunger rod stops and the injection is complete, carefully remove the needle from the injection site.
","After you have given the injection, roll the unconscious person on to their side to prevent choking.Call for emergency medical help or a healthcare provider right away after you have injected ZEGALOGUE. Even if the ZEGALOGUE injection helps the person to wake up, still call for emergency medical help right away. If the person does not respond after 15 minutes, another dose may be given, if available.Once the person is able to safely consume food or drink, give the person a fast-acting source of sugar (such as fruit juice) and a long-acting source of sugar (such as crackers with cheese or peanut butter).Replace the used ZEGALOGUE right away so you will have a new ZEGALOGUE in case you need it.
After injection
••••
","sweatingdrowsinessdizzinesssleep disturbancesirregular heartbeat (palpitation)anxietytremorblurred visionhungerslurred speechrestlessnessdepressed moodtingling in the hands, feet, lips, or tongueirritabilityabnormal behaviorlightheadednessunsteady movementinability to concentratepersonality changesheadache
••••••••••
••••••••••
","
If not treated early, hypoglycemia may worsen and the person may have severe hypoglycemia. Signs of severe hypoglycemia include confusion, seizures, unconsciousness, and death.
","made of a heavy-duty plasticcan be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come outupright and stable during useleak-resistantproperly labeled to warn of hazardous waste inside the containerWhen your sharps disposal container is almost full, you will need to follow your community guidelines for the correct way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposalDo not dispose of your used sharps disposal container in your household trash unless your community guidelines permit it.Do not recycle your used sharps disposal container.
How to throw away (dispose of) ZEGALOGUE
Dispose of your ZEGALOGUE and the gray needle cover in an FDA-cleared sharps disposal container.Put your expired or used needles and syringes in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash.If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
•••••
","Do not use ZEGALOGUE if the:expiration date has passedgray cap is missing orautoinjector appears damagedWhen opening the red protective case make sure to hold it up straight (with the gray lid on top) to avoid dropping ZEGALOGUE.Do not remove the gray cap until you are ready to inject ZEGALOGUE.For questions or more information about ZEGALOGUE, call your healthcare provider.
Read before injecting ZEGALOGUE
•ooo•••
","Store ZEGALOGUE in the refrigerator between 36°F to 46°F (2°C to 8°C).Do not freeze.Store ZEGALOGUE in the red protective case it comes in.ZEGALOGUE can also be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 12 months. See example to the right for how to keep track of this 12-month period.Do not return to refrigerator after storing at room temperature.Throw away ZEGALOGUE if it has been stored at room temperature for more than 12 months.Replace ZEGALOGUE before the expiration date printed on the red protective case.Keep ZEGALOGUE and all medicines out of the reach of children.
Storage information
••••••••
","
Description of parts
","Outer upper armsLower abdomen (at least 2 inches from the belly button)Front or back of thighsButtocksRoll back any clothing to expose bare skin. Do not inject through clothes.Hold the red protective case upright with the gray lid on top.Pull the gray lid up to open.Carefully remove ZEGALOGUE from the red protective case without dropping it.
Before injection
Choose injection site and expose skinInjection sites include:
••••
Hold the red protective case upright and remove gray lid
•••
","
How to inject
Step 1Remove the gray cap from needle endPull the gray cap straight off.Do not put your hand or fingers anywhere near the yellow needle guard. Touching the yellow needle guard may cause an accidental needle stick injury.
Step 2Push and hold down ZEGALOGUE for 10 seconds and check window is redPush ZEGALOGUE straight down on skin until the yellow needle guard is fully pressed down. You may hear the first click.Keep holding ZEGALOGUE down and slowly count to 10 seconds. During this time the medicine window will turn red and you may hear a second click.Check that the medicine window is red, which means that the full dose has been given.
Step 3 Remove ZEGALOGUE from injection siteRemove ZEGALOGUE by lifting it straight up.The yellow needle guard will cover the needle and lock, preventing an accidental needle stick injury.
","After you have given the injection, roll the unconscious person on to their side to prevent choking.Call for emergency medical help or a healthcare provider right away after you have injected ZEGALOGUE. Even if the ZEGALOGUE injection helps the person to wake up, still call for emergency medical help right away. If the person does not respond after 15 minutes, another dose may be given, if available.Once the person is able to safely consume food or drink, give the person a fast-acting source of sugar (such as fruit juice) and a long-acting source of sugar (such as crackers with cheese or peanut butter).Replace the used ZEGALOGUE right away so you will have a new ZEGALOGUE in case you need it.
After injection
••••
","sweatingdrowsinessdizzinesssleep disturbancesirregular heartbeat (palpitation)anxietytremorblurred visionhungerslurred speechrestlessnessdepressed moodtingling in the hands, feet, lips, or tongueirritabilityabnormal behaviorlightheadednessunsteady movementinability to concentratepersonality changesheadache
••••••••••
••••••••••
","
If not treated early, hypoglycemia may worsen and the person may have severe hypoglycemia. Signs of severe hypoglycemia include confusion, seizures, unconsciousness, and death.
","made of a heavy-duty plasticcan be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come outupright and stable during useleak-resistantproperly labeled to warn of hazardous waste inside the containerWhen your sharps disposal container is almost full, you will need to follow your community guidelines for the correct way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used autoinjectors. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposalDo not dispose of your used sharps disposal container in your household trash unless your community guidelines permit it.Do not recycle your used sharps disposal container.
How to throw away (dispose of) ZEGALOGUE
Dispose of your ZEGALOGUE and gray cap in an FDA-cleared sharps disposal container.Put your expired or used ZEGALOGUE in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) autoinjectors, loose needles and syringes in your household trash.If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
•••••
"],"spl_patient_package_insert":["Patient Information ZEGALOGUE (ze' gah log) (dasiglucagon) injection, for subcutaneous use What is ZEGALOGUE? ZEGALOGUE is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in people with diabetes aged 6 years and older. It is not known if ZEGALOGUE is safe and effective in children under 6 years of age. Do not use ZEGALOGUE if you: • have a tumor called pheochromocytoma in the gland on top of your kidneys (adrenal gland). • have a tumor called insulinoma in your pancreas. Before using ZEGALOGUE, tell your healthcare provider about all of your medical conditions, including if you: • have a tumor in your pancreas. • are allergic to dasiglucagon or any other ingredients in ZEGALOGUE. See the end of this Patient Information for a complete list of ingredients in ZEGALOGUE. • have not had food or water for a long time (prolonged fasting or starvation). • have adrenal insufficiency. • have low blood sugar that does not go away (chronic hypoglycemia). • are pregnant or plan to become pregnant. • are breastfeeding or plan to breastfeed. It is not known if ZEGALOGUE passes into your breast milk. You and your healthcare provider should decide if you can use ZEGALOGUE while breastfeeding. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should I use ZEGALOGUE? • Read the detailed Instructions For Use that come with ZEGALOGUE. • Use ZEGALOGUE exactly how your healthcare provider tells you to use it. • Make sure your caregiver knows where you keep your ZEGALOGUE and how to use ZEGALOGUE the right way before you need it. • Your caregiver must act quickly. Having very low blood sugar for a period of time may be harmful. • Your healthcare provider will tell you how and when to use ZEGALOGUE. • After giving ZEGALOGUE, your caregiver should call for emergency medical help right away. • Once you are able to safely consume food or drink, your caregiver should give you a fast-acting source of sugar (such as fruit juice) and a long-acting source of sugar (such as crackers with cheese or peanut butter). • If you do not respond to treatment after 15 minutes, your caregiver may give you another dose, if available. • Tell your healthcare provider each time you use ZEGALOGUE. Your healthcare provider may need to change the dose of your other diabetes medicines. What are the possible side effects of ZEGALOGUE? ZEGALOGUE may cause serious side effects, including: • high blood pressure . ZEGALOGUE can cause high blood pressure in certain people with tumors in their adrenal glands. • low blood sugar . ZEGALOGUE can cause certain people with tumors in their pancreas called insulinomas to have low blood sugar. • serious allergic reaction . Call your healthcare provider or get medical help right away if you have a serious allergic reaction including: rash, difficulty breathing, or low blood pressure (hypotension). The most common side effects of ZEGALOGUE include: 1. Adults 2. nausea 3. vomiting 4. headache 5. diarrhea 6. injection site pain 1. Children 2. nausea 3. vomiting 4. headache 5. injection site pain These are not all of the possible side effects of ZEGALOGUE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store ZEGALOGUE? • Store ZEGALOGUE in a refrigerator between 36°F to 46°F (2°C to 8°C). • Do not freeze ZEGALOGUE. • ZEGALOGUE can also be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 12 months. See example in the Instructions For Use for how to keep track of this 12-month period. • Do not return ZEGALOGUE to the refrigerator after storing at room temperature. • Throw away ZEGALOGUE if it has been stored at room temperature for more than 12 months. • Replace ZEGALOGUE before the expiration date printed on the red protective case. • Store ZEGALOGUE in the red protective case it comes in. Keep ZEGALOGUE and all medicines out of the reach of children. General information about the safe use of ZEGALOGUE. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZEGALOGUE for a condition for which it was not prescribed. Do not give ZEGALOGUE to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ZEGALOGUE that is written for healthcare professionals. What are the ingredients in ZEGALOGUE? Active ingredient: dasiglucagon, provided as dasiglucagon hydrochloride Inactive ingredients: tromethamine, sodium chloride and water for injection. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH Distributed by: Novo Nordisk Inc., Plainsboro, NJ, USA Manufactured by: Rechon Life Science AB, Malmö, Sweden For more information go to www.zegalogue.com or call 1-800-727-6500. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 01/2023"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available data on dasiglucagon use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated hypoglycemia in pregnancy can cause complications and may be fatal. In animal reproduction studies, daily subcutaneous administration of dasiglucagon to pregnant rabbits and rats during the period of organogenesis did not cause adverse developmental effects at exposures 7 and 709 times the human dose of 0.6 mg based on AUC, respectively (see Data ) . Data Animal Data In an embryo-fetal development study, pregnant rats were treated daily with subcutaneous doses of 2, 10, and 24 mg/kg/day during the period of organogenesis (gestation day 6 to 17). Maternal toxicity, in terms of decreased body weight gain, lower fetal body weight, and delayed bone ossification, was observed at ≥10 mg/kg/day (≥475 times the human dose, based on AUC). In an embryo-fetal development study, pregnant rabbits were treated daily with subcutaneous doses of 0.1, 0.3, and 1 mg/kg/day during the period of organogenesis (gestation day 6 to 19). Lower fetal body weight and delayed bone ossification were observed at 1 mg/kg/day (100 times the human dose, based on AUC), a dose that also induced maternal toxicity in terms of decreased body weight gain. At ≥0.3 mg/kg/day (≥20 times the human dose), dasiglucagon caused fetal skeletal and visceral malformations. No adverse fetal developmental effects were observed at 0.1 mg/kg/day, corresponding to exposure 7 times the human dose. 8.2 Lactation Risk Summary There is no information on the presence of dasiglucagon in either human or animal milk, or the effects of the drug on the breastfed infant or milk production. Dasiglucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is therefore unlikely to cause harm to an exposed infant. 8.4 Pediatric Use The safety and effectiveness of ZEGALOGUE for the treatment of severe hypoglycemia in patients with diabetes have been established in pediatric patients aged 6 years and above. Use of ZEGALOGUE for this indication is supported by evidence from a study in 42 pediatric patients with type 1 diabetes [see Clinical Studies (14.2) ] . The safety and effectiveness of ZEGALOGUE have not been established in pediatric patients younger than 6 years of age. 8.5 Geriatric Use Clinical studies of ZEGALOGUE included too few patients 65 years of age and older to determine whether these patients respond differently from younger adult patients."],"spl_patient_package_insert_table":["have a tumor called pheochromocytoma in the gland on top of your kidneys (adrenal gland).have a tumor called insulinoma in your pancreas.have a tumor in your pancreas.are allergic to dasiglucagon or any other ingredients in ZEGALOGUE. See the end of this Patient Information for a complete list of ingredients in ZEGALOGUE.have not had food or water for a long time (prolonged fasting or starvation).have adrenal insufficiency.have low blood sugar that does not go away (chronic hypoglycemia).are pregnant or plan to become pregnant.are breastfeeding or plan to breastfeed. It is not known if ZEGALOGUE passes into your breast milk. You and your healthcare provider should decide if you can use ZEGALOGUE while breastfeeding.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.Read the detailed Instructions For Use that come with ZEGALOGUE.Use ZEGALOGUE exactly how your healthcare provider tells you to use it.Make sure your caregiver knows where you keep your ZEGALOGUE and how to use ZEGALOGUE the right way before you need it.Your caregiver must act quickly. Having very low blood sugar for a period of time may be harmful.Your healthcare provider will tell you how and when to use ZEGALOGUE.After giving ZEGALOGUE, your caregiver should call for emergency medical help right away.Once you are able to safely consume food or drink, your caregiver should give you a fast-acting source of sugar (such as fruit juice) and a long-acting source of sugar (such as crackers with cheese or peanut butter).If you do not respond to treatment after 15 minutes, your caregiver may give you another dose, if available.Tell your healthcare provider each time you use ZEGALOGUE. Your healthcare provider may need to change the dose of your other diabetes medicines.high blood pressure. ZEGALOGUE can cause high blood pressure in certain people with tumors in their adrenal glands.low blood sugar. ZEGALOGUE can cause certain people with tumors in their pancreas called insulinomas to have low blood sugar.serious allergic reaction. Call your healthcare provider or get medical help right away if you have a serious allergic reaction including: rash, difficulty breathing, or low blood pressure (hypotension).The most common side effects of ZEGALOGUE include:Adultsnauseavomitingheadachediarrheainjection site painChildrennauseavomitingheadacheinjection site painStore ZEGALOGUE in a refrigerator between 36°F to 46°F (2°C to 8°C).Do not freeze ZEGALOGUE.ZEGALOGUE can also be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 12 months. See example in the Instructions For Use for how to keep track of this 12-month period.Do not return ZEGALOGUE to the refrigerator after storing at room temperature.Throw away ZEGALOGUE if it has been stored at room temperature for more than 12 months.Replace ZEGALOGUE before the expiration date printed on the red protective case.Store ZEGALOGUE in the red protective case it comes in.Keep ZEGALOGUE and all medicines out of the reach of children.
Patient Information ZEGALOGUE (ze' gah log) (dasiglucagon) injection, for subcutaneous use
What is ZEGALOGUE? ZEGALOGUE is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in people with diabetes aged 6 years and older. It is not known if ZEGALOGUE is safe and effective in children under 6 years of age.
Do not use ZEGALOGUE if you:
••
Before using ZEGALOGUE, tell your healthcare provider about all of your medical conditions, including if you:
•••••••
How should I use ZEGALOGUE?
•••••••••
What are the possible side effects of ZEGALOGUE? ZEGALOGUE may cause serious side effects, including:
•••
1.2.3.4.5.6.
1.2.3.4.5.
These are not all of the possible side effects of ZEGALOGUE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ZEGALOGUE?
•••••••
General information about the safe use of ZEGALOGUE. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZEGALOGUE for a condition for which it was not prescribed. Do not give ZEGALOGUE to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ZEGALOGUE that is written for healthcare professionals.
What are the ingredients in ZEGALOGUE? Active ingredient: dasiglucagon, provided as dasiglucagon hydrochloride Inactive ingredients: tromethamine, sodium chloride and water for injection. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH Distributed by: Novo Nordisk Inc., Plainsboro, NJ, USAManufactured by: Rechon Life Science AB, Malmö, SwedenFor more information go to www.zegalogue.com or call 1-800-727-6500.
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 01/2023
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 0.6 mg/0.6 mL Prefilled Syringe 1ct Carton Emergency Use for Very Low Blood Sugar ZEGALOGUE ® (dasiglucagon) injection 0.6 mg/0.6 mL* Prefilled Syringe Single-Dose Injection, for subcutaneous use. Rx only NDC 0169-1913-01 List: 191301 Carton contents: 1 Single-Dose Prefilled Syringe 1 Prescribing Information OPEN HERE Novo Nordisk ® Carton - PFS - 1ct","PRINCIPAL DISPLAY PANEL - 0.6 mg/0.6 mL Prefilled Syringe 2ct Carton Emergency Use for Very Low Blood Sugar ZEGALOGUE ® (dasiglucagon) injection 0.6 mg/0.6 mL* Prefilled Syringe 2 Single-Dose Prefilled Syringes Injection, for subcutaneous use. Rx only Novo Nordisk ® NDC 0169-1913-02 List: 191302 Carton contents: 2 Single-Dose Prefilled Syringes 2 Prescribing Information OPEN HERE 2 PACK Carton - PFS - 2ct","Package/Label Display Panel - 0.6 mg/0.6 mL 1ct Autoinjector Carton Emergency Use for Very Low Blood Sugar ZEGALOGUE ® (dasiglucagon) injection 0.6 mg/0.6 mL* Autoinjector Single-Dose Injection, for subcutaneous use. Rx only NDC 0169-1912-01 List: 191201 Carton contents: 1 Single-Dose Autoinjector 1 Prescribing Information OPEN HERE Novo Nordisk ® Carton - AI - 1ct","Package/Label Display Panel - 0.6 mg/0.6 mL 2ct Autoinjector Carton Emergency Use for Very Low Blood Sugar ZEGALOGUE ® (dasiglucagon) injection 0.6 mg/0.6 mL* Autoinjector 2 Single-Dose Autoinjectors Injection, for subcutaneous use. Rx only Novo Nordisk ® NDC 0169-1912-02 List: 191202 Carton contents: 2 Single-Dose Autoinjectors 2 Prescribing Information OPEN HERE 2 PACK Carton-AI-2ct"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long-term studies in animals to evaluate carcinogenicity of dasiglucagon have not been performed. Mutagenesis Dasiglucagon was not mutagenic or clastogenic in a standard battery of genotoxicity tests: bacterial mutagenicity (Ames), human lymphocyte chromosome aberration, and rat bone marrow micronucleus. Impairment of Fertility In a fertility and early embryofetal development study in rats, dasiglucagon administered by subcutaneous injection (0.5, 2, and 8 mg/kg/day) did not impair fertility in male and female rats at exposures 179 and 269 times the human dose of 0.6 mg (based on AUC), respectively."]},"tags":[{"label":"Antihypoglycemic Agent","category":"class"},{"label":"Peptide","category":"modality"},{"label":"Glucagon receptor","category":"target"},{"label":"GCGR","category":"gene"},{"label":"H04AA02","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Hypoglycemia due to diabetes mellitus","category":"indication"},{"label":"Zealand Pharma","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"14 reports"},{"date":"","signal":"DISABILITY","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"MEMORY IMPAIRMENT","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"STAPHYLOCOCCAL INFECTION","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"AMINO ACID LEVEL DECREASED","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ARTHRITIS","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BACK PAIN","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BLOOD GLUCAGON DECREASED","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BLOOD GLUCOSE FLUCTUATION","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BURNING SENSATION","source":"FDA FAERS","actionTaken":"1 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"57%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"25%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"11%","severity":"mild","_validated":true},{"effect":"Diarrhea","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Injection site pain","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Hypertension","drugRate":"reported","severity":"unknown"},{"effect":"Hypotension","drugRate":"reported","severity":"unknown"},{"effect":"Bradycardia","drugRate":"reported","severity":"unknown"},{"effect":"Presyncope","drugRate":"reported","severity":"unknown"},{"effect":"Palpitations","drugRate":"reported","severity":"unknown"},{"effect":"Orthostatic intolerance","drugRate":"reported","severity":"unknown"}],"contraindications":["Insulinoma","Pheochromocytoma"],"specialPopulations":{"Lactation":"There is no information on the presence of dasiglucagon in either human or animal milk, or the effects of the drug on the breastfed infant or milk production. Dasiglucagon is peptide and would be expected to be broken down to its constituent amino acids in the infants digestive tract and is therefore unlikely to cause harm to an exposed infant.","Pregnancy":"There are no available data on dasiglucagon use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated hypoglycemia in pregnancy can cause complications and may be fatal. In animal reproduction studies, daily subcutaneous administration of dasiglucagon to pregnant rabbits and rats during the period of organogenesis did not cause adverse developmental effects at exposures and 709 times the human dose of 0.6 mg based on AUC, respectively.","Geriatric use":"Clinical studies of ZEGALOGUE included too few patients 65 years of age and older to determine whether these patients respond differently from younger adult patients.","Paediatric use":"The safety and effectiveness of ZEGALOGUE for the treatment of severe hypoglycemia in patients with diabetes have been established in pediatric patients aged 6 years and above. Use of ZEGALOGUE for this indication is supported by evidence from study in 42 pediatric patients with type 1 diabetes."}},"trials":[],"aliases":[],"company":"Zealand Pharma","patents":[{"applNo":"N214231","source":"FDA Orange Book","status":"Active","expires":"Jan 6, 2034","useCode":"U-3752","territory":"US","drugProduct":false,"patentNumber":"11795204","drugSubstance":false},{"applNo":"N214231","source":"FDA Orange Book","status":"Active","expires":"Feb 3, 2035","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10442847","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DASIGLUCAGON","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:11:47.622640+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:11:42.360600+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:11:53.445740+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:11:41.346243+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DASIGLUCAGON","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:11:53.786993+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:40.901708+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:40.901749+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:40.901755+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:11:55.241347+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucagon receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:11:54.834199+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297741/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:11:54.492155+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA214231","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:40.901759+00:00"}},"allNames":"zegalogue","offLabel":[],"synonyms":["dasiglucagon","dasiglucagon hydrochloride","zegalogue","ZP4207"],"timeline":[{"date":"2021-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ZEALAND PHARMA AS to Zealand Pharma"},{"date":"2021-03-22","type":"positive","source":"DrugCentral","milestone":"FDA approval (Zealand Pharma As)"},{"date":"2026-03-22","type":"negative","source":"FDA Orange Book","milestone":"New Chemical Entity exclusivity expires"},{"date":"2035-02-03","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 10442847 expires"}],"aiSummary":"Zegalogue (DASIGLUCAGON) is a small molecule antihypoglycemic agent developed by Zealand Pharma, targeting the glucagon receptor. It was FDA-approved in 2021 for the treatment of hypoglycemia due to diabetes mellitus. Zegalogue is a patented medication with no generic manufacturers available. Key safety considerations include its potential to cause nausea, vomiting, and headache. As a glucagon receptor agonist, it works by stimulating the release of glucose from stored energy sources in the body.","approvals":[{"date":"2021-03-22","orphan":false,"company":"ZEALAND PHARMA AS","regulator":"FDA"}],"brandName":"Zegalogue","ecosystem":[{"indication":"Hypoglycemia due to diabetes mellitus","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Glucagon receptor","novelty":"Follow-on","targets":[{"gene":"GCGR","source":"DrugCentral","target":"Glucagon receptor","protein":"Glucagon receptor"}],"moaClass":"Glucagon Receptor Agonists","modality":"Small Molecule","drugClass":"Antihypoglycemic Agent [EPC]","explanation":"Dasiglucagon is glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect.","oneSentence":"Zegalogue works by stimulating the release of glucose from stored energy sources in the body.","technicalDetail":"Zegalogue acts as a glucagon receptor agonist, binding to the glucagon receptor and activating the G-protein coupled receptor pathway, which ultimately leads to the activation of adenylate cyclase and the increase in intracellular cyclic AMP (cAMP) levels, resulting in the mobilization of glucose from glycogen stores and the promotion of gluconeogenesis."},"commercial":{"launchDate":"2021","_launchSource":"DrugCentral (FDA 2021-03-22, ZEALAND PHARMA AS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5447","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DASIGLUCAGON","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DASIGLUCAGON","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:25:51.148334","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:11:58.108757+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"glucagon","drugSlug":"glucagon","fdaApproval":"1960-11-14","patentExpiry":"Sep 23, 2039","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"NCE","date":"Mar 22, 2026"},{"code":"NCE","date":"Mar 22, 2026"}],"genericName":"dasiglucagon","indications":{"approved":[{"name":"Hypoglycemia due to diabetes mellitus","source":"DrugCentral","snomedId":237633009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Zealand Pharma","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glucagon","brandName":"glucagon","genericName":"glucagon","approvalYear":"1960","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03941236","phase":"PHASE3","title":"Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zealand Pharma","startDate":"2019-05-02","conditions":["Congenital Hyperinsulinism"],"enrollment":42,"completionDate":"2026-12-31"},{"nctId":"NCT06588504","phase":"PHASE1","title":"Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-09-10","conditions":["Diabetes Mellitus, Type 1"],"enrollment":38,"completionDate":"2025-07-20"},{"nctId":"NCT05378672","phase":"PHASE3","title":"A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2023-05-09","conditions":["Hypoglycemia","Type 1 Diabetes"],"enrollment":8,"completionDate":"2024-12-03"},{"nctId":"NCT04172441","phase":"PHASE2,PHASE3","title":"Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2020-06-19","conditions":["Congenital Hyperinsulinism"],"enrollment":12,"completionDate":"2022-03-07"},{"nctId":"NCT05454709","phase":"PHASE2","title":"A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System","status":"WITHDRAWN","sponsor":"Inreda Diabetic B.V.","startDate":"2023-12-29","conditions":["Diabetes Mellitus, Type 1"],"enrollment":0,"completionDate":"2023-12-29"},{"nctId":"NCT03777176","phase":"PHASE3","title":"A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2019-02-07","conditions":["Congenital Hyperinsulinism"],"enrollment":32,"completionDate":"2020-10-05"},{"nctId":"NCT04192019","phase":"EARLY_PHASE1","title":"Micro Glucagon During Exercise in Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-04","conditions":["Type 1 Diabetes","Hypoglycemia"],"enrollment":0,"completionDate":"2024-06"},{"nctId":"NCT03895697","phase":"PHASE3","title":"A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2019-03-26","conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"],"enrollment":92,"completionDate":"2019-07-30"},{"nctId":"NCT04824872","phase":"PHASE2","title":"Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults","status":"WITHDRAWN","sponsor":"Zealand Pharma","startDate":"2023-02","conditions":["Hypoglycemia","Glucose Metabolism Disorders"],"enrollment":0,"completionDate":"2023-02"},{"nctId":"NCT04836273","phase":"PHASE2","title":"Treatment of Post-bariatric Hypoglycaemia","status":"COMPLETED","sponsor":"Filip Krag Knop","startDate":"2021-08-20","conditions":["Hyperinsulinemic Hypoglycemia","Postprandial Hypoglycemia"],"enrollment":24,"completionDate":"2022-12-15"},{"nctId":"NCT04764968","phase":"PHASE2","title":"Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2021-04-27","conditions":["Type 1 Diabetes","Hypoglycemia"],"enrollment":24,"completionDate":"2022-01-28"},{"nctId":"NCT03667053","phase":"PHASE3","title":"Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children","status":"COMPLETED","sponsor":"Zealand Pharma","isPivotal":true,"startDate":"2018-09-28","conditions":["Hypoglycemia"],"enrollment":42,"completionDate":"2019-06-28"},{"nctId":"NCT03378635","phase":"PHASE3","title":"A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects","status":"COMPLETED","sponsor":"Zealand Pharma","isPivotal":true,"startDate":"2017-12-07","conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"],"enrollment":170,"completionDate":"2018-05-25"},{"nctId":"NCT03688711","phase":"PHASE3","title":"Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM","status":"COMPLETED","sponsor":"Zealand Pharma","isPivotal":true,"startDate":"2018-11-01","conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"],"enrollment":45,"completionDate":"2019-03-11"},{"nctId":"NCT03216226","phase":"PHASE3","title":"A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2017-06-28","conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"],"enrollment":112,"completionDate":"2018-02-13"},{"nctId":"NCT02971228","phase":"PHASE2","title":"Feasibility Trial Testing the Bionic Pancreas With ZP4207","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2016-11","conditions":["Diabetes Mellitus, Type 1"],"enrollment":13,"completionDate":"2017-06-07"},{"nctId":"NCT03735225","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2018-11-07","conditions":["Hypoglycemia"],"enrollment":60,"completionDate":"2019-06-24"},{"nctId":"NCT04449692","phase":"PHASE2","title":"Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2020-07-02","conditions":["Type 1 Diabetes","Hypoglycemia"],"enrollment":20,"completionDate":"2021-01-04"},{"nctId":"NCT03984370","phase":"PHASE2","title":"Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2019-09-18","conditions":["Hyperinsulinemic Hypoglycemia","Postprandial Hypoglycemia"],"enrollment":10,"completionDate":"2020-02-26"},{"nctId":"NCT03840278","phase":"PHASE2,PHASE3","title":"The Bihormonal iLet Bionic Pancreas Feasibility Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-05-15","conditions":["Type 1 Diabetes Mellitus"],"enrollment":12,"completionDate":"2019-07-03"},{"nctId":"NCT02916251","phase":"PHASE2","title":"ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2016-12-01","conditions":["Diabetes Mellitus Type 1"],"enrollment":38,"completionDate":"2017-04-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT03378635","NCT03688711","NCT03667053"],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Zegalogue"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"39407","NDDF":"018680","UNII":"AD4J2O47FQ","VANDF":"4040381","INN_ID":"10480","RXNORM":"2535233","UMLSCUI":"C5139868","chemblId":"CHEMBL4297741","ChEMBL_ID":"CHEMBL4297741","KEGG_DRUG":"D11359","DRUGBANK_ID":"DB15226","PUBCHEM_CID":"126961379","MESH_SUPPLEMENTAL_RECORD_UI":"C000710373"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2021-","companyName":"Zealand Pharma As","relationship":"Original Developer"},{"period":"present","companyName":"Zealand Pharma","relationship":"Current Owner"}],"publicationCount":47,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"H04AA02","allCodes":["H04AA02"]},"biosimilarFilings":[],"originalDeveloper":"Zealand Pharma As","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Zealand Pharma","companyId":"zealand-pharma","modality":"Small Molecule","firstApprovalDate":"2021","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-03-22T00:00:00.000Z","mah":"ZEALAND PHARMA AS","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-03-22T00:00:00.000Z","mah":"ZEALAND PHARMA","brand_name_local":null,"application_number":"NDA214231"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":"EMEA/H/C/006214"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zegalogue","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":6,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:11:58.108757+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}